Top

Molecular Cancer

Published in:

Open Access 01-12-2010 | Research

The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia

Authors: Jasmin R Agarwal, Frank Griesinger, Walter Stühmer, Luis A Pardo

Published in: Molecular Cancer | Issue 1/2010

Abstract

Background

The voltage-gated potassium channel hEag1 (K_V10.1) has been related to cancer biology. The physiological expression of the human channel is restricted to the brain but it is frequently and abundantly expressed in many solid tumors, thereby making it a promising target for a specific diagnosis and therapy. Because chronic lymphatic leukemia has been described not to express hEag1, it has been assumed that the channel is not expressed in hematopoietic neoplasms in general.

Results

Here we show that this assumption is not correct, because the channel is up-regulated in myelodysplastic syndromes, chronic myeloid leukemia and almost half of the tested acute myeloid leukemias in a subtype-dependent fashion. Most interestingly, channel expression strongly correlated with increasing age, higher relapse rates and a significantly shorter overall survival. Multivariate Cox regression analysis revealed hEag1 expression levels in AML as an independent predictive factor for reduced disease-free and overall survival; such an association had not been reported before. As a functional correlate, specific hEag1 blockade inhibited the proliferation and migration of several AML cell lines and primary cultured AML cells in vitro.

Conclusion

Our observations implicate hEag1 as novel target for diagnostic, prognostic and/or therapeutic approaches in AML.

Available only for authorised users

Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T: Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res. 2005, 11: 1416-1424. 10.1158/1078-0432.CCR-04-1552CrossRefPubMed

Muñoz L, Nomdedeu JF, Villamor N, Guardia R, Colomer D, Ribera JM, Torres JP, Berlanga JJ, Fernández C, Llorente A: Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells. Leukemia. 2003, 17: 76-82. 10.1038/sj.leu.2402708CrossRefPubMed

Zwaan CM, Meshinchi S, Radich JP, Veerman AJ, Huismans DR, Munske L, Podleschny M, Hahlen K, Pieters R, Zimmermann M: FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood. 2003, 102: 2387-2394. 10.1182/blood-2002-12-3627CrossRefPubMed

Ostendorf P, Seeber S: Hämatologie/Onkologie. 1997, Munich: Urban & Fischer Verlag

Stühmer W, Alves F, Hartung F, Zientkowska M, Pardo LA: Potassium channels as tumour markers. FEBS Lett. 2006, 580: 2850-2852. 10.1016/j.febslet.2006.03.062CrossRefPubMed

Shieh CC, Coghlan M, Sullivan JP, Gopalakrishnan M: Potassium channels: Molecular defects, diseases, and therapeutic opportunities. Pharmacol Rev. 2000, 52: 557-593.PubMed

Wulff H, Castle NA, Pardo LA: Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov. 2009, 8: 982-1001. 10.1038/nrd2983PubMedCentralCrossRefPubMed

Camacho J, Sánchez A, Stühmer W, Pardo LA: Cytoskeletal interactions determine the electrophysiological properties of human EAG potassium channels. Pflugers Arch. 2000, 441: 167-174. 10.1007/s004240000420CrossRefPubMed

Gómez-Varela D, Zwick-Wallasch E, Knötgen H, Sánchez A, Hettmann T, Ossipov D, Weseloh R, Contreras-Jurado C, Rothe M, Stühmer W, Pardo LA: Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity. Cancer Res. 2007, 67: 7343-7349. 10.1158/0008-5472.CAN-07-0107CrossRefPubMed

10.

Hemmerlein B, Weseloh RM, Mello de Queiroz F, Knötgen H, Sánchez A, Rubio ME, Martin S, Schliephacke T, Jenke M, Radzun HJ: Overexpression of Eag1 potassium channels in clinical tumour specimens. Mol Cancer. 2006, 5: 41- 10.1186/1476-4598-5-41PubMedCentralCrossRefPubMed

11.

Mello de Queiroz F, Suárez-Kurtz G, Stühmer W, Pardo LA: Ether à go-go potassium channel expression in soft tissue sarcoma patients. Mol Cancer. 2006, 5: 42- 10.1186/1476-4598-5-42PubMedCentralCrossRefPubMed

12.

Pardo LA, del Camino D, Sánchez A, Alves F, Brüggemann A, Beckh S, Stühmer W: Oncogenic potential of EAG K⁺ channels. EMBO J. 1999, 18: 5540-5547. 10.1093/emboj/18.20.5540PubMedCentralCrossRefPubMed

13.

Pardo LA, Stühmer W: Eag1: an emerging oncological target. Cancer Res. 2008, 68: 1611-1613. 10.1158/0008-5472.CAN-07-5710CrossRefPubMed

14.

Martin S, Lino de Oliveira C, Mello de Queiroz F, Pardo LA, Stühmer W, Del Bel E: Eag1 potassium channel immunohistochemistry in the CNS of adult rat and selected regions of human brain. Neuroscience. 2008, 155: 833-844. 10.1016/j.neuroscience.2008.05.019CrossRefPubMed

15.

Bijlenga P, Occhiodoro T, Liu JH, Bader CR, Bernheim L, Fischer- Lougheed J: An ether-a-go-go K⁺ current, ih-eag, contributes to the hyperpolarization of human fusion-competent myoblasts. J Physiol. 1998, 512: 317-323. 10.1111/j.1469-7793.1998.317be.xPubMedCentralCrossRefPubMed

16.

Pardo LA, Brüggemann A, Camacho J, Stühmer W: Cell cycle-related changes in the conducting properties of r-eag K⁺ channels. J Cell Biol. 1998, 143: 767-775. 10.1083/jcb.143.3.767PubMedCentralCrossRefPubMed

17.

Schönherr R, Lober K, Heinemann SH: Inhibition of human ether a go-go potassium channels by Ca²⁺/calmodulin. EMBO J. 2000, 19: 3263-3271. 10.1093/emboj/19.13.3263PubMedCentralCrossRefPubMed

18.

Meyer R, Heinemann SH: Characterization of an eag-like potassium channel in human neuroblastoma cells. J Physiol. 1998, 508: 49-56.PubMedCentralCrossRefPubMed

19.

Farias LMB, Bermúdez Ocaña D, Díaz L, Larrea F, Avila-Chávez E, Cadena A, Hinojosa LM, Lara G, Villanueva LA, Vargas C: Ether à go-go Potassium Channels as Human Cervical Cancer Markers. Cancer Res. 2004, 64: 6996-7001. 10.1158/0008-5472.CAN-04-1204CrossRefPubMed

20.

Downie BR, Sánchez A, Knötgen H, Contreras-Jurado C, Gymnopoulos M, Weber C, Stühmer W, Pardo LA: Eag1 expression interferes with hypoxia homeostasis and induces angiogenesis in tumors. J Biol Chem. 2008, 283: 36234-36240. 10.1074/jbc.M801830200PubMedCentralCrossRefPubMed

21.

Gavrilova-Ruch O, Schönherr K, Gessner G, Schönherr R, Klapperstuck T, Wohlrab W, Heinemann SH: Effects of imipramine on ion channels and proliferation of IGR1 melanoma cells. J Membr Biol. 2002, 188: 137-149. 10.1007/s00232-001-0181-3CrossRefPubMed

22.

Ouadid-Ahidouch H, Le Bourhis X, Roudbaraki M, Toillon RA, Delcourt P, Prevarskaya N: Changes in the K⁺ current-density of MCF-7 cells during progression through the cell cycle: Possible involvement of a h-ether.a-gogo K⁺ channel. Recept Channels. 2001, 7: 345-356.PubMed

23.

Weber C, Mello de Queiroz F, Downie B, Sukow A, Stühmer W, Pardo LA: Silencing the activity and proliferative properties of the human Eag1 potassium channel by RNAi. J Biol Chem. 2006, 281: 13033-13037. 10.1074/jbc.M600883200. 10.1074/jbc.M600883200CrossRef

24.

Smith GAM, Tsui HW, Newell EW, Jiang XP, Zhu XP, Tsui FWL, Schlichter LC: Functional up-regulation of HERG K⁺ channels in neoplastic hematopoietic cells. Journal of Biological Chemistry. 2002, 277: 18528-18534. 10.1074/jbc.M200592200CrossRefPubMed

25.

García-Ferreiro RE, Kerschensteiner D, Major F, Monje F, Stühmer W, Pardo LA: Mechanism of Block of hEag1 K⁺ Channels by Imipramine and Astemizole. J Gen Physiol. 2004, 124: 301-317. 10.1085/jgp.200409041PubMedCentralCrossRefPubMed

26.

Pillozzi S, Brizzi MF, Balzi M, Crociani O, Cherubini A, Guasti L, Bartolozzi B, Becchetti A, Wanke E, Bernabei PA: HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors. Leukemia. 2002, 16: 1791-1798. 10.1038/sj.leu.2402572CrossRefPubMed

27.

Li H, Liu L, Guo L, Zhang J, Du W, Li X, Liu W, Chen X, Huang S: HERG K⁺ channel expression in CD34⁺/CD38^-/CD123^(high) cells and primary leukemia cells and analysis of its regulation in leukemia cells. International journal of hematology. 2008, 87: 387-392. 10.1007/s12185-008-0056-9CrossRefPubMed

28.

Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrozek K, Baldus CD, Vukosavljevic T, Liu CG, Ross ME: High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood. 2008, 111: 5371-5379. 10.1182/blood-2007-11-124958PubMedCentralCrossRefPubMed

29.

Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S, Thomas X, Raffoux E, Lamandin C, Castaigne S: Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood. 2002, 100: 2717-2723. 10.1182/blood-2002-03-0990CrossRefPubMed

30.

Bianchi L, Wible B, Arcangeli A, Taglialatela M, Morra F, Castaldo P, Crociani O, Rosati B, Faravelli L, Olivotto M, Wanke E: HERG encodes a K⁺ current highly conserved in tumors of different histogenesis - a selective advantage for cancer cells?. Cancer Res. 1998, 58: 815-822.PubMed

31.

Pillozzi S, Brizzi MF, Bernabei PA, Bartolozzi B, Caporale R, Basile V, Boddi V, Pegoraro L, Becchetti A, Arcangeli A: VEGFR-1 (FLT-1), beta1 integrin, and hERG K⁺ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood. 2007, 110: 1238-1250. 10.1182/blood-2006-02-003772CrossRefPubMed

32.

Sanguinetti MC, Tristani-Firouzi M: hERG potassium channels and cardiac arrhythmia. Nature. 2006, 440: 463-469. 10.1038/nature04710CrossRefPubMed

33.

Feldman DL, Mogelesky TC: Use of Histopaque for isolating mononuclear cells from rabbit blood. Journal of immunological methods. 1987, 102: 243-249. 10.1016/0022-1759(87)90083-4CrossRefPubMed

34.

Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucl Acids Res. 2001, 29: e45- 10.1093/nar/29.9.e45PubMedCentralCrossRefPubMed

35.

Ahmed N, Williams JF, Weidemann MJ: The human promyelocytic HL60 cell line: a model of myeloid cell differentiation using dimethylsulphoxide, phorbol ester and butyrate. Biochemistry international. 1991, 23: 591-602.PubMed

36.

Meyer PA, Kleinschnitz C: Retinoic acid induced differentiation and commitment in HL-60 cells. Environmental health perspectives. 1990, 88: 179-182. 10.2307/3431071PubMedCentralCrossRefPubMed

37.

Trayner ID, Bustorff T, Etches AE, Mufti GJ, Foss Y, Farzaneh F: Changes in antigen expression on differentiating HL60 cells treated with dimethylsulphoxide, all-trans retinoic acid, alpha1, 25-dihydroxyvitamin D3 or 12-O-tetradecanoyl phorbol-13-acetate. Leukemia research. 1998, 22: 537-547. 10.1016/S0145-2126(98)00041-1CrossRefPubMed

38.

Lawless JF: Statistical Models and Methods for Lifetime Data Book Description. 2002, New York: Wiley Interscience, 2CrossRef

Title: The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia
Authors: Jasmin R Agarwal
Frank Griesinger
Walter Stühmer
Luis A Pardo
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-9-18

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2010

Nicotine-induced survival signaling in lung cancer cells is dependent on their p53 status while its down-regulation by curcumin is independent

The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization

Maslinic acid potentiates the anti-tumor activity of tumor necrosis factor α by inhibiting NF-κB signaling pathway

Role of the atypical chemoattractant receptor CRAM in regulating CCL19 induced CCR7 responses in B-cell chronic lymphocytic leukemia

Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors

Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old

Keynote webinar | Spotlight on antibody–drug conjugates in cancer